High failure rates in clinical trials, estimated at up to 90%, remain a major hurdle in drug development, with poor ADME (Absorption, Distribution, Metabolism, and Excretion) properties being one of the leading causes of late-stage attrition. Among these ADME-related challenges, low oral bioavailability is particularly prevalent, especially in the case of oral solid dosage forms. OSDs continue to be the preferred route of administration due to their convenience, patient compliance, and manufacturing scalability. 

However, many promising drug candidates fail to achieve sufficient systemic exposure because of solubility and permeability limitations, metabolic instability, or formulation-related issues. These failures not only delay development timelines but also increase costs and risk the viability of otherwise effective therapies. 

To mitigate these challenges, it is critical to identify and implement an appropriate enabling formulation strategy early in the development process. Doing so can de-risk your program and reduce costs through reducing the need for repeated reformulation work, and accelerated timelines. 

This guide introduces the UpperSolv™ platform, a science-driven solution designed to streamline the development of oral formulations with improved bioavailability. Built to support rapid decision-making, UpperSolv™ leverages minimal API and time to provide formulation insights that are both predictive and actionable. Whether you’re working with a poorly soluble compound, a challenging pharmacokinetic profile, or early-stage data, this platform helps you identify the most effective path forward. Therefore, minimising risk while maximising the potential for clinical and commercial success.

DOWNLOAD THE GUIDE BELOW!